This expression of interest (EOI) addresses the global challenge of tuberculosis (TB) prevention in children, who constitute 12% of global TB cases. Despite the severity of the issue, less than half of affected children are notified by National TB Programmes, indicating a significant case detection gap.
In response, a new paediatric formulation, a dispersible tablet (DT), has been developed through collaboration with Unitaid and The Aurum Institute NPC under the IMPAACT4TB project. This paediatric formulation, approved and listed on the Global Drug Facility’s catalogue, aims to offer a more family-friendly, patient-centred approach to TPT.
Unitaid has established the Early Market Access Vehicle (EMAV) to accelerate access to this innovative paediatric formulation. Interested governments and partners are invited to submit an EOI to participate in the EMAV, which aims to secure 85,000 patient courses from the first production phase. The EMAV is expected to increase access to a more affordable and user-friendly TPT product, thereby addressing the current challenges in administering TB preventive therapy to children.
Beginning on 1 December 2023, the Aurum Institute will accept Expressions of Interest (EOI) to the EMAV on a rolling basis through 30 October 2024 (or when total volume commitment is approved, whichever comes first). Parties interested in participation in the EMAV may submit an EOI using the response form (see below) during this time.
Interested partners should review the EOI or reach out to impaact4tb@auruminstitute.org for more information.
Product Brief for the Paediatric-friendly rifapentine and isoniazid for 3HP and 1HP TB preventive treatment (TPT)
